Martin Worley Group Makes New $369,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Martin Worley Group purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,000 shares of the specialty pharmaceutical company's stock, valued at approximately $369,000.

Several other institutional investors have also bought and sold shares of JAZZ. Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after acquiring an additional 115,102 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. GW&K Investment Management LLC lifted its position in Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock valued at $57,142,000 after acquiring an additional 97,589 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock worth $13,800,000 after purchasing an additional 93,422 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $11,373,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Remove Ads

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. The trade was a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 in the last quarter. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded down $0.71 during trading hours on Tuesday, reaching $106.23. The company's stock had a trading volume of 453,352 shares, compared to its average volume of 757,892. The stock has a market cap of $6.45 billion, a PE ratio of 14.97, a PEG ratio of 1.04 and a beta of 0.42. The business has a 50-day simple moving average of $131.92 and a 200 day simple moving average of $123.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

Wall Street Analyst Weigh In

Several research firms have commented on JAZZ. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Needham & Company LLC restated a "buy" rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price target for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Buy" and an average target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.